Drug Comparison

PillID

Pill Identifier Drug Encyclopedia Drug Classes Compare Interactions Blog 🌙

Jardiance vs Farxiga

Jardiance (empagliflozin) and Farxiga (dapagliflozin) are both sodium-glucose cotransporter-2 (SGLT2) inhibitors — a class that has transformed the treatment of type 2 diabetes, heart failure, and chronic kidney disease over the past decade. Both lower blood glucose by causing the kidneys to excrete excess sugar in urine, and both have demonstrated cardiovascular and renal protective effects that go well beyond glucose control. The differences between them are primarily in the specific trial data and the precise scope of their FDA-approved indications.

Quick Comparison

Feature	Empagliflozin (Jardiance)	Dapagliflozin (Farxiga)
Drug Class	SGLT2 inhibitor	SGLT2 inhibitor
Generic Name	Empagliflozin	Dapagliflozin
Brand Name	Jardiance	Farxiga
Approved For	Type 2 diabetes (glycemic control), CV death reduction in T2D with CVD, heart failure (HFrEF), CKD	Type 2 diabetes, heart failure (HFrEF and HFpEF), CKD (broader indication), risk reduction in T2D with CVD
Available as Generic	No	No
Key Advantage	EMPA-REG OUTCOME trial (CV mortality reduction in T2D+CVD); strong HFrEF data; once daily	DAPA-HF (HFrEF) and DELIVER (HFpEF) trials — only SGLT2i approved for both HF types; DAPA-CKD covers broader CKD population; once daily
Main Drawback	Not approved for heart failure with preserved ejection fraction (HFpEF); no generic available	No generic available; CV mortality data from EMPA-REG may edge out DECLARE-TIMI for some endpoints

How They're Similar

Both drugs inhibit SGLT2, a transporter in the proximal tubule of the kidney responsible for reabsorbing roughly 90% of filtered glucose. By blocking this transporter, both drugs cause glucosuria (glucose excretion in urine), lowering blood sugar independent of insulin. This mechanism also promotes osmotic diuresis and natriuresis (sodium excretion), which contributes to blood pressure reduction and the cardiorenal protective effects observed in clinical trials.

The side effect profiles are nearly identical: genital mycotic infections (yeast infections, particularly in women), urinary tract infections, increased urination, and a small but real risk of diabetic ketoacidosis (DKA) — including euglycemic DKA where blood glucose may not be dramatically elevated. Fournier's gangrene (necrotizing fasciitis of the perineum), while rare, has been reported with the entire class. Both require adequate kidney function to work and become less effective as eGFR declines.

Key Differences

Heart failure with preserved EF (HFpEF): The most clinically important current distinction is that dapagliflozin is FDA-approved for heart failure with preserved ejection fraction (HFpEF) based on the DELIVER trial — a major unmet need given HFpEF has far fewer proven therapies than HFrEF. Empagliflozin has strong data in HFrEF but its HFpEF indication has a more limited scope, making Farxiga uniquely positioned for the full heart failure spectrum.

CKD indication: Both drugs have CKD indications, but dapagliflozin's DAPA-CKD trial included patients with and without diabetes — demonstrating kidney protection independent of glycemic effects. This gives Farxiga a broader CKD population approval.

Cardiovascular mortality data: The EMPA-REG OUTCOME trial for empagliflozin showed a particularly robust signal for cardiovascular death reduction in T2D patients with established CVD — this mortality benefit was one of the first of its kind for a glucose-lowering drug and generated significant clinical enthusiasm for Jardiance. Dapagliflozin's DECLARE-TIMI 58 trial showed CV benefit but with a broader, lower-risk population and slightly different endpoint results.

No head-to-head trials: No large randomized trial has directly compared empagliflozin and dapagliflozin head-to-head. Differences in trial populations, endpoints, and designs make cross-trial comparisons imperfect.

Empagliflozin: Strengths & Weaknesses

Strengths: Robust CV mortality data from EMPA-REG OUTCOME in high-risk T2D patients, strong HFrEF indication (EMPEROR-Reduced trial), once daily, well-established safety profile.

Weaknesses: Not approved for HFpEF. No generic available. May be less preferred when HFpEF is the primary heart failure concern.

Dapagliflozin: Strengths & Weaknesses

Strengths: Only SGLT2 inhibitor approved for both HFrEF and HFpEF, broad CKD indication covering non-diabetic CKD, extensive cardiorenal outcome data across a wide patient population.

Weaknesses: No generic available. CV mortality signal in DECLARE-TIMI slightly less pronounced than EMPA-REG for certain endpoints in head-to-head narrative comparisons.

Frequently Asked Questions